|
Name |
(1R,3E,5S,15S)-5,17-dihydroxy-18-[(2S)-1-hydroxypropan-2-yl]-4,8,12,15-tetramethylbicyclo[13.3.0]octadeca-3,8,12,17-tetraen-16-one
|
Molecular Formula | C25H38O4 | |
IUPAC Name* |
(1R,3E,5S,15S)-5,17-dihydroxy-18-[(2S)-1-hydroxypropan-2-yl]-4,8,12,15-tetramethylbicyclo[13.3.0]octadeca-3,8,12,17-tetraen-16-one
|
|
SMILES |
CC1=CCCC(=CC[C@]2([C@H](C/C=C(/[C@H](CC1)O)\C)C(=C(C2=O)O)[C@H](C)CO)C)C
|
|
InChI |
InChI=1S/C25H38O4/c1-16-7-6-8-17(2)13-14-25(5)20(11-10-18(3)21(27)12-9-16)22(19(4)15-26)23(28)24(25)29/h7,10,13,19-21,26-28H,6,8-9,11-12,14-15H2,1-5H3/b16-7?,17-13?,18-10+/t19-,20-,21+,25+/m1/s1
|
|
InChIKey |
UTGBBPSEQPITLF-YBDHUMTRSA-N
|
|
Synonyms |
Terpestacin
|
|
CAS | NA | |
PubChem CID | 138404408 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 402.6 | ALogp: | 2.9 |
HBD: | 3 | HBA: | 4 |
Rotatable Bonds: | 2 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 77.8 | Aromatic Rings: | 2 |
Heavy Atoms: | 29 | QED Weighted: | 0.535 |
Caco-2 Permeability: | -4.551 | MDCK Permeability: | 0.00002040 |
Pgp-inhibitor: | 0.988 | Pgp-substrate: | 0.002 |
Human Intestinal Absorption (HIA): | 0.082 | 20% Bioavailability (F20%): | 0.901 |
30% Bioavailability (F30%): | 0.154 |
Blood-Brain-Barrier Penetration (BBB): | 0.824 | Plasma Protein Binding (PPB): | 81.69% |
Volume Distribution (VD): | 2.148 | Fu: | 7.71% |
CYP1A2-inhibitor: | 0.037 | CYP1A2-substrate: | 0.194 |
CYP2C19-inhibitor: | 0.042 | CYP2C19-substrate: | 0.651 |
CYP2C9-inhibitor: | 0.044 | CYP2C9-substrate: | 0.094 |
CYP2D6-inhibitor: | 0.01 | CYP2D6-substrate: | 0.063 |
CYP3A4-inhibitor: | 0.774 | CYP3A4-substrate: | 0.422 |
Clearance (CL): | 15.374 | Half-life (T1/2): | 0.063 |
hERG Blockers: | 0.013 | Human Hepatotoxicity (H-HT): | 0.263 |
Drug-inuced Liver Injury (DILI): | 0.179 | AMES Toxicity: | 0.026 |
Rat Oral Acute Toxicity: | 0.082 | Maximum Recommended Daily Dose: | 0.895 |
Skin Sensitization: | 0.957 | Carcinogencity: | 0.876 |
Eye Corrosion: | 0.006 | Eye Irritation: | 0.03 |
Respiratory Toxicity: | 0.654 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC001882 | 1.000 | D00ZFP | 0.239 | ||||
ENC002974 | 1.000 | D0P1FO | 0.224 | ||||
ENC003210 | 0.802 | D0KR5B | 0.221 | ||||
ENC005683 | 0.722 | D04GJN | 0.217 | ||||
ENC006130 | 0.676 | D01CKY | 0.215 | ||||
ENC005684 | 0.663 | D04ATM | 0.215 | ||||
ENC004109 | 0.656 | D0K0EK | 0.212 | ||||
ENC005685 | 0.656 | D02ZGI | 0.212 | ||||
ENC004376 | 0.576 | D0T2PL | 0.212 | ||||
ENC003502 | 0.408 | D08SVH | 0.212 |